TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Investor Securities Class Action Lawsuit 11/04/2015

  • If you purchased shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI), you may have certain options. Please contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Lawsuit Overview

Case Dismissed
Company
Spectrum Pharmaceuticals, Inc.
Security
NASDAQ: SPPI

Case Name
Spectrum Pharmaceuticals Shareholder Class Action Lawsuit 11/04/2015
Type of Lawsuit
Shareholder Class Action
Court of Filing
U.S. District Court for the District of Nevada

Class Period Begin
Class Period End
You must register or login to receive notifications.

Click here to subscribe to Spectrum Pharmaceuticals, Inc..
Summary

December 15, 2015 (Update) - The case was voluntarily dismissed.

November 09, 2015 (Shareholders Foundation) - An investor in shares of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) filed a lawsuit in the U.S. District Court for the District of Nevada over alleged violations of Federal Securities Laws by Spectrum Pharmaceuticals, Inc. in connection with certain allegedly false and misleading statements made between May 7, 2015 and October 23, 2015.

According to the complaint the plaintiff alleges on behalf of purchasers of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) common shares between May 7, 2015 and October 23, 2015, that the defendants violated Federal Securities Laws.

On October 23, 2015, Spectrum Pharmaceuticals, Inc announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA). Spectrum Pharmaceuticals, Inc said that in the letter, the FDA did not identify any clinical deficiency in Spectrum's NDA package.

Shares of Spectrum Pharmaceuticals, Inc (NASDAQ:SPPI) declined on October 23, 2015 to as low as $4.89 per share.